Design, Synthesis, Antitumor activity, cell cycle analysis and ELISA assay for Cyclin Dependant Kinase-2 of a new (4-aryl-6-flouro-4H-benzo[4, 5] thieno[3, 2-b] pyran) derivatives.
DOI:
https://doi.org/10.13171/mjc65/01709262240-zaherAbstract
A series of benzo[b]thiophene and their benzo[4,5]thieno[3,2-b]pyran derivatives (3a-f), (4a-f), (5a-f) and 6 were synthesized and characterized by spectroscopic and elemental analysis. All compounds were subjected to one dose anticancer screening in NCI- America, but only the compounds gave high percent growth inhibition were further subjected to five dose screening. A good result of compound 4f with GI50 = 0.15 µmol, TGI= 1.14 µmol and 4c with GI50 = 1.09 µmol, TGI = 10.19 µmol, LC50 = 100 µmol on HT-29 cell line. To explore mechanism of cytotoxicity, compound 4f and 4c were allowed to affect cell cycle progression using HT-29 cell line (human colon cancer) in two-time interval (24 and 48 hr). The cytotoxicity of 4f and 4c was correlated with induction of apoptosis causing pre-G1apoptosis and cell growth arrest at G2/M in a time dependant manner through inhibition of CDK-2. For exploring the SAR for all synthesized compounds, IC50 of 5d was determined which was equal to 0.32 ±0.05 µmol, IC50 of 6 was equal to be 0.15 ±0.01 µmol while IC50 of erlotinib reference was equal to 0.3±0.02 µmol. Finally we were able to synthesize a series of benzo[b] thiophene, benzo[4,5]thieno[3,2-b]pyran having a good cytotoxic activity suggesting promising anticancer derivatives.References
J. F. Kerr, A.H. Wyllie, and A.R. Currie, Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. British journal of cancer, 1972. 26(4), 239.
G. Häcker, The morphology of apoptosis. Cell and tissue research, 2000. 301(1), 5-17.
F. H. Igney and P.H. Krammer, Death and anti-death: tumour resistance to apoptosis. Nature Reviews Cancer, 2002. 2(4), 277-288.
J. F. Kerr, C.M. Winterford, and B.V. Harmon, Apoptosis. Its significance in cancer and cancer therapy. Cancer, 1994. 73(8), 2013-2026.
N. Morales, et al., Synthesis, Biological Evaluation, and Molecular Simulation of Chalcones and Aurones as Selective MAO-B Inhibitors. Chemical biology & drug design, 2015. 85(6), 685-695.
S. K. Warkhade and K.P. Kakade, Synthesis and characterization of substituted 5 bromo 2-benzylidine-1-benzofuran-3-one and its structural determination.
H. Sedlacek, et al., Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. International journal of oncology, 1996. 9(6), 143-1168.
N. J. Lawrence, et al., The total synthesis of an aurone isolated from Uvaria hamiltonii: aurones and flavones as anticancer agents. Bioorganic & medicinal chemistry letters, 2003. 13(21), 3759-3763.
M. Cushman, D. Nagarathnam, and R.L. Geahlen, Synthesis and evaluation of hydroxylated flavones and related compounds as potential inhibitors of the protein-tyrosine kinase p56lck. Journal of natural products, 1991. 54(5), 1345-1352.
M. T. Konieczny, et al., Synthesis and cytostatic activity of 4, 7-dihydroxythioaurone derivatives. Effect of B ring substitution on the activity. Chemical and pharmaceutical bulletin, 2006. 54(3), 350-353.
B. C. Jennings,et al., 2-Bromopalmitate and 2-(2-hydroxy-5-nitro-benzylidene)-benzo [b] thiophen-3-one inhibit DHHC-mediated palmitoylation in vitro. Journal of lipid research, 2009. 50(2), 233-242.
I. A. Prior, et al., GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. Nature Cell Biology, 2001, 3(4), 368-375.
A. F. Zaher, et al., Synthesis, antitumor screening and cell cycle analysis of novel benzothieno [3, 2-b] pyran derivatives. Journal of enzyme inhibition and medicinal chemistry, 2016. 31(sup4), 145-153.
A. E. Hammam, Novel fluoro substituted benzo [b] pyran with anti-lung cancer activity. 2005.
C. E. Dalgliesh and F.G. Mann, 237. The comparative reactivity of the carbonyl groups in the thionaphthenquinones. Part II. The influence of substituent groups in the thionaphthenquinones. Journal of the Chemical Society (Resumed), 1945, 893-909.
M. Bakhouch, et al., Michael addition of active methylene compounds to (Z)-2-arylidenebenzo [b] thiophen-3 (2H)-ones. Mediterranean Journal of Chemistry, 2015. 4(1), 9-17.
M. Bakhouch, et al., Crystal structure of ethyl 2-amino-4-(4-chlorophenyl)-4H-1-benzothieno [3, 2-b] pyran-3-carboxylate. Acta Crystallographica Section E: Crystallographic Communications, 2015. 71(8), o619-o620.
P. Pozarowski, and Z. Darzynkiewicz, Analysis of cell cycle by flow cytometry. Checkpoint Controls and Cancer: Volume 2: Activation and Regulation Protocols, 2004, 301-311.
B. R. Walker, et al., Davidson's principles and practice of medicine. 22nd edition. ed. 2014, Edinburgh ; New York: Churchill Livingstone/Elsevier. xix, 1372 pages.
R. H. Shoemaker, The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer, 2006. 6(10): p. 813-823.
Z. A. Stewart, M.D. Westfall, and J.A. Pietenpol, Cell-cycle dysregulation and anticancer therapy. Trends in Pharmacological Sciences, 2003. 24(3): p. 139-145.
D. Wlodkowic, J. Skommer, and Z. Darzynkiewicz, Flow cytometry-based apoptosis detection. Methods in molecular biology (Clifton, N.J.), 2009. 559: p. 10.1007/978-1-60327-017-5_2.
J. J. Luke, et al., The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and phase I clinical trial. Clinical Cancer Research, 2012.
J. Rolff, et al., Preclinical study of a combination of erlotinib and bevacizumab in early stages of unselected non-small cell lung cancer patient-derived xenografts. Targeted oncology, 2016. 11(4): p. 507-514.
D. R. Spigel, et al., Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. 2014, American Society of Clinical Oncology.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
